Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 2,201–2,300 of 4,108
Osteoporosis Care Gap After Hip Fracture – Worse With Low Healthcare Access and Quality
Galli, S. H., Weiss, D. M., Beck, A. P., & Scerpella, T. A. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.09.002 · Cited by 8
Gleich, J., Kußmaul, A. C., Steiner, E. A., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06246-1 · Cited by 6
“5 standard deviations (SD), osteoporosis by a T-score < − 2/5 SD [19].”
BackgroundWang, F., Tong, T., Miao, D., et al. (2022) · International Orthopaedics · doi:10.1007/s00264-022-05327-y · Cited by 6
Hsu, C., Huang, W., Chen, H., & Lai, J. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-11066-2 · Cited by 6
Premature Ovarian Insufficiency
Gunning, M. N., Troìa, L., Janse, F., Luisi, S. V., & Fauser, B. C. J. M. (2020) · Endocrinology · doi:10.1007/978-3-030-14782-2_15 · Cited by 6
Xiong, M., Xue, Y., Zhu, W., Deng, A., Tan, Z., Zhou, G., & Xiang, N. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054158 · Cited by 6
The current role of telehealth in the management of patients with osteoporosis
Lewiecki, E. M., & Bouchonville, M. F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2078304 · Cited by 7
Self-citationLiu, Q., Han, G., Li, R., Fan, D., Du, G., Zhang, M., Tao, L., Li, H., Liu, D., & Song, C. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060703 · Cited by 6
The proportion of Thai postmenopausal women who would be eligible for anti-osteoporosis therapy
Chanidkul, P., Sribenjalak, D., Charoenngam, N., & Pongchaiyakul, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279829 · Cited by 8
“An analysis of the National Health and Nutrition Examination Survey III of 1,754 women aged>50 years revealed that 37.4% met the 2008 NOF treatment threshold, and the proportion increased with age from 17.0% among those aged 50–59 years to 87.5% among those aged>80 years [15].”
BackgroundInfluentialOmer, M., Ngo, C., Ali, H., Orlovskaya, N. A., Cheong, V. S., Ballesteros, A., Garner, M. T., Wynn, A., Martyniak, K., Wei, F., et al. (2023) · Nutrients · doi:10.3390/nu15051209 · Cited by 7
Osteoporosis and vitamin D consumption: knowledge and practice in different Arab countries
Saleh, A. A., Shibli, F., Masri, J. E., et al. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01298-8 · Cited by 6
“Secondary osteoporosis occurs on top of an underlying trigger, such as metabolic diseases and deficiencies, medications, immobilization, and malignancy [4-6].”
Racial and Ethnic Disparities in Metabolic Bone Disease
Maldonado, L. Y., Bosques, L., CROMER, S. J., Azar, S. S., Yu, E. W.-Y., & Burnett‐Bowie, S. M. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.05.004 · Cited by 6
Galasso, A. C., Herzog, L. N., Sekar, M., et al. (2023) · Injury · doi:10.1016/j.injury.2023.110985 · Cited by 6
Elmasry, G. F., Ali, R. A., El-kady, D. S., et al. (2023) · Drug Development Research · doi:10.1002/ddr.22104 · Cited by 6
Fan, C., Wu, X., Ji, Z., Zhang, L., Zhou, F., & Mao, H. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.10.052 · Cited by 9
Bone Health in the Transgender Population
Goodrich, E., Walcott, Q. A., Dallman, J., Crow, H., & Templeton, K. J. (2023) · JBJS Reviews · doi:10.2106/jbjs.rvw.23.00123 · Cited by 7
Inhibition of PPP1R15A alleviates osteoporosis via suppressing RANKL-induced osteoclastogenesis
Ding, Z., Chen, Y., Zheng, Y., Wang, Y., Deng, W., Zheng, J., Yang, Q. Z., Chen, Z., Li, L., Jiang, H., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01209-0 · Cited by 7
Ruangnopparut, R., Charoensri, S., Sribenjalak, D., Theerakulpisut, D., & Pongchaiyakul, C. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s448659 · Cited by 10
Efficacy and Safety of Generic Alendronate for Osteoporosis Treatment
Jarusriwanna, A., Malisorn, S., Tananoo, S., Areewong, K., Rasamimongkol, S., & Laoruengthana, A. (2024) · Orthopedic Research and Reviews · doi:10.2147/orr.s445202 · Cited by 7
The Triple Burden of Osteoporosis, Sarcopenia, and Aging in Geriatrics (review)
Kurmaev, D. P., Bulgakova, S. V., Treneva, E. V., Kosareva, O. V., Sharonova, L. A., & Dolgikh, Y. A. (2024) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-3-2024-225-239 · Cited by 15
Monaco, M. D., Castiglioni, C., Vallero, F., Monaco, R. D., & Tappero, R. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0532-z · Cited by 6
How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility?
Yoon, D.-H., Choi, D., Jung, H.-G., et al. (2014) · Asian Spine Journal · doi:10.4184/asj.2014.8.6.729 · Cited by 6
Female College Students' Knowledge, Self-efficacy and Health Behaviors related to Bone Health
Oh, E. G., Ko, I. S., Chu, S. H., et al. (2012) · Korean journal of women health nursing/Yeoseong geon'gang ganho hag'hoeji/Yeoseong geon-gang ganho hakoeji · doi:10.4069/kjwhn.2012.18.1.38 · Cited by 6
Sympathetic Skin Response and Vasomotor Symptoms in Postmenopausal Osteoporotic Women.
Ashraf, A., Roshanzamir, S., Bemana, G., Mohammadi, A., Jahani, N., & Naseri, M. (2015) · PubMed Central · Cited by 7
Bone Health Evaluation in a Veteran Population: A Need for the Fracture Risk Assessment Tool (FRAX)
Ackman, J. M., Lata, P. F., Schuna, A. A., & Elliott, M. E. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014542149 · Cited by 6
Naylor, K. L., Zou, G., Leslie, W. D., McArthur, E., Lam, N. N., Knoll, G. A., Kim, S., Fraser, L.-A., Adachi, J. D., Hodsman, A. B., et al. (2016) · Canadian Journal of Kidney Health and Disease · doi:10.1186/s40697-016-0092-y · Cited by 7
Osteoporosis and Mechanisms of Skeletal Aging
Glowacki, J., & Vokes, T. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_10 · Cited by 8
Evenson, A. L., & Sanders, G. F. (2015) · Californian Journal of Health Promotion · doi:10.32398/cjhp.v13i2.1826 · Cited by 7
Nash, L. A., Peters, S. J., Sullivan, P., & Ward, W. E. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13050460 · Cited by 6
Protecting bone in long-term HIV positive patients receiving antiretrovirals
McGinty, T., & Mallon, P. W. G. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1184570 · Cited by 8
Predictors of bone mineral density testing among older women on Medicare
Lou, Y., Edmonds, S. W., Jones, M., Ullrich, F. A., Wehby, G. L., Cram, P. M., & Wolinsky, F. D. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3688-2 · Cited by 7
Correlation between ultrasonic power spectrum and bone density on the heel
Xu, Y., Yang, X., Ding, Z., et al. (2016) · Ultrasonics · doi:10.1016/j.ultras.2016.08.023 · Cited by 6
Factors associated with the accuracy of self-reported osteoporosis in the community
Cunningham, T. D., & DeShields, S. C. (2016) · Rheumatology International · doi:10.1007/s00296-016-3573-5 · Cited by 6
Guiducci, L., Maffei, S., Sabatino, L., Zyw, L., Battaglia, D. B. R., Vannucci, A., Cecco, P. D., & Vassalle, C. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1270932 · Cited by 6
Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study
Lin, S.-Y., Lin, C., Ju, S.-W., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173125 · Cited by 6
Bone Health in Parkinson’s Disease
Riancho‐Zarrabeitia, L., & Delgado‐Alvarado, M. (2017) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-017-9232-x · Cited by 6
Physical Activity for Fall and Fracture Prevention
Ponzano, M., Rodrigues, I. B., & Giangregorio, L. (2018) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-018-0103-5 · Cited by 9
Haroon, M., Khan, K., Thong, L., et al. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1882-2 · Cited by 6
Guan, W., Yu, W., Lin, Q., et al. (2018) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2018.09.004 · Cited by 6
Hurtado, I., García‐Sempere, A., Rodríguez-Bernal, C. L., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00768 · Cited by 6
Sadat‐Ali, M., Al-Dakheel, D. A., Almousa, S. A., AlAnii, F. M., Ebrahim, W. Y., ALOmar, H. K., Alsayed, H. N., Acharya, S., & Alhawaj, H. (2019) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s204099 · Cited by 6
No major reduction in bone mineral density after long-term treatment of patients with Celiac Disease
Hære, P., Høie, O., Lundin, K. E. A., & Haugeberg, G. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.07.024 · Cited by 7
The Application of PRECEDE Model on Preventing Osteoporosis in Women
Jeihooni, A. K., Ghasemi, M., Mobaraei, A., Jamshidi, H., & Harsini, P. A. (2019) · Clinical Nursing Research · doi:10.1177/1054773819865874 · Cited by 10
“Bone density of women in all ages is significantly less than men with same ages and in both sexes the maximum bone density is obtained up to the age of 30 and then, by getting older, bone density reduces (Cosman et al., 2014).”
BackgroundEffect of Tart Cherry Polyphenols on Osteoclast Differentiation and Activity
Thomas, A., South, S. M., Vijayagopal, P., & Juma, S. (2019) · Journal of Medicinal Food · doi:10.1089/jmf.2019.0050 · Cited by 7
The relation between the RANKL and resistin in menopausal women with osteoporosis
Al-Masaoodi, R. A., AL-Sallami, A. S. M., & Al-Baseesee, H. H. (2019) · AIP conference proceedings · doi:10.1063/1.5123113 · Cited by 9
El-Haroun, H., Soliman, M., soliman, M., & El-Gawad, S. A. (2020) · The Egyptian Journal of Histology · doi:10.21608/ejh.2020.18855.1193 · Cited by 9
“5 standard deviation (SD) or more below the standard for juvenile healthy women as evaluated by dual energy x-ray absorptiometry (DEXA)[1].”
BackgroundInfluentialNayak, S., & Greenspan, S. L. (2020) · Osteoporosis International · doi:10.1007/s00198-019-05258-2 · Cited by 6
Trabecular bone scores in young HIV-infected men: a matched case-control study
Kim, Y. J., Kang, K. Y., Shin, J., Jun, Y. H., Kim, S. I., & Kim, Y. R. (2020) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-020-3092-0 · Cited by 7
McDonald, A. M., Yang, E. S.-H., Saag, K. G., et al. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-0711-1 · Cited by 6
Guðmundsdóttir, S. L., Hrafnkelsson, H. T. J., Sigurdsson, E., & Jóhannsson, E. (2020) · Public Health Nutrition · doi:10.1017/s1368980019004142 · Cited by 8
“The subjects in the current study are probably in the final stages of a period of peak bone accretion(29), and although the variance of peak bone mass is largely genetically determined, environmental and modifiable factors, such as adequate intake of 25(OH)D, are also important(30) as maximising peak bonemass may cont…”
BackgroundEffects of whole-body vibration training on bone density and turnover markers in adolescent swimmers
Marín-Puyalto, J., Gómez‐Cabello, A., González‐Agüero, A., Matute-Llorente, Á., Gómez‐Bruton, A., Jürimäe, J., Casajús, J. A., & Vicente‐Rodríguez, G. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0400 · Cited by 6
What Messages About Osteoporosis Are Offered in Spanish Videos on YouTube?
Tejada-Llacsa, P. J., Díaz-Sánchez, P., Villagaray-Pacheco, N., Meregildo-Silverio, M. R., & Cabello-León, E. (2020) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001375 · Cited by 6
“O steoporosis is a frequently occurring bone disease whose incidence increases with age, and that represents a public health problem.(1) It is estimated that approximately 49million people in North America, Europe, Japan, and Australia combined have osteoporosis.”
BackgroundInterscholastic Athletics and Bone Strength: The Iowa Bone Development Study
Pashkova, A., Hartman, J. M., Letuchy, E. M., & Janz, K. F. (2020) · The Journal of Strength and Conditioning Research · doi:10.1519/jsc.0000000000003646 · Cited by 8
“Bone health is particularly important for women because of the greater risk of osteoporosis in postmenopausal women (4).”
Lee, S. H., Lee, J. Y., Lim, K.-H., Lee, Y., Kim, S.-H., Choi, S., Cho, S.-H., & Koh, J. (2020) · Calcified Tissue International · doi:10.1007/s00223-020-00731-1 · Cited by 6
Hsu, S.-L., Chou, W., Hsu, C., Ko, J., Jhan, S.-W., Wang, C., Lee, M., Hsu, T.-C., & Cheng, J. (2020) · Biomedicines · doi:10.3390/biomedicines8120614 · Cited by 6
“Pharmaceutical approaches include antiresorptive and st ulating agents, whereas nonphar aceutical approaches i clude exercise programs and biophy ical interventions [7,8].”
BackgroundKiweewa, F. M., Nabwana, M., Kiwanuka, N., Scholes, D., Isingel, E., Nolan, M. L., Fowler, M. G., Musoke, P., Pettifor, J. M., Brown, T. T., et al. (2020) · JBMR Plus · doi:10.1002/jbm4.10446 · Cited by 6
“0 SD at any of the three sites (LS, TH, and FN) in accordance with the National Osteoporosis Foundation guidelines definition.((27,28))”
MethodIn Silico Network Analysis of Ingredients of Cornus officinalis in Osteoporosis
Huang, F., Guo, H., Wei, Y., et al. (2021) · Medical Science Monitor · doi:10.12659/msm.929219 · Cited by 6
“Clinically, the treatment of the different types of osteoporosis mainly consists of antiresorptive agents and anabolic agents, including calcium, vitamin D, bisphosphonates, and calcitonin [6,7].”
BackgroundAssociations between Diet Quality and Anthropometric Measures in White Postmenopausal Women
Arikawa, A. Y., & Kurzer, M. S. (2021) · Nutrients · doi:10.3390/nu13061947 · Cited by 8
“It is thought that adequate calcium and vitamin D intake is especially important after menopause due to the decreases in bone mineral density associated with lower circulating estrogen [27], but controversy exists about the relationship between calcium and vitamin D intake and bone mineral density or risk of fractures.”
BackgroundOtonari, J., Ikezaki, H., Furusyo, N., & Sudo, N. (2021) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001840 · Cited by 6
“Intake of sufficient nutrients, such as vitamin D and calcium; sun exposure; and hormonal factors associated with sleep, are important for better bone formation.(22) Therefore, maintaining a regular life cycle, including breakfast and sleep, is beneficial for fracture prevention.”
BackgroundPostmenopausal osteoporosis: current status of bone densitometry
Testini, V., PAPARELLA, M. T., GANGAI, I., & GUGLIELMI, G. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.20.04674-2 · Cited by 7
Jehle, S., Häuselmann, H., Keschawarzi, M., Lamy, O., Luzuy, F., Marcoli, N., Meier, C., Uebelhart, B., & Wiedersheim, P. (2022) · Healthcare · doi:10.3390/healthcare10020295 · Cited by 10
“Importantly, osteopenia and osteoporosis represent a continuum, and in absolute terms more patients with osteopenia experience a fragility fracture than patients with osteoporosis, as osteopenia is far more common [12].”
BackgroundVarela, A. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-56192-9_6 · Cited by 6
Niu, S., Chen, M., Yan, D., Liu, X., Guo, S., Ou, L., Fan, H., Lv, J., Wang, Q., Dong, W., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893166 · Cited by 7
“…order to exploratory and analyze the effect of LY0600 on the early clinical stage, bone turnover markers were used as PD indicators instead of fractures and bone mineral density on the basis of existing guidelines (Cosman et al.,(Cosman et al., 2014), Kanis et al., 2019, Qaseem et al., 2017).”
MethodWang, X., Xu, X., Oates, M. K., Hill, T., & Wade, R. L. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01135-4 · Cited by 6
ORWOLL, E. S., Vanderschueren, D., & Boonen, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00032-7 · Cited by 8
Bone Health in autoimmune inflammatory rheumatic diseases
Benlidayı, İ. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85831-1.00002-4 · Cited by 7
Evaluation of the Patient at Risk for Osteoporosis
Lewiecki, E. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00063-7 · Cited by 8
Self-citationOdanacatib: An Emerging Novel Treatment Alternative for Postmenopausal Osteoporosis
Schultz, T. C., Valenzano, J. P., Verzella, J. L., & Umland, E. M. (2015) · Women s Health · doi:10.2217/whe.15.39 · Cited by 7
Jeon, J., Lee, S. Y., Im, Y., et al. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.001 · Cited by 6
Potential Clinical Impact of Abdominal Aortic Calcification on Bone Density Lateral Spine Images
Schousboe, J. T., Richter, S. A., & Beran, M. S. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2016.06.002 · Cited by 6
Wilczek, M. L., Kälvesten, J., Bergström, I. B., Pernow, Y., Sääf, M., Freyschuss, B., & Brismar, T. B. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.006 · Cited by 7
Eom, S.-Y., Yim, D.-H., Hong, S.-M., et al. (2017) · Human & Experimental Toxicology · doi:10.1177/0960327117705425 · Cited by 6
Oleson, C. V. (2017) · Springer eBooks · doi:10.1007/978-3-319-45084-1_3 · Cited by 6
Peningkatan asupan kalsium menghambat penurunan kepadatan tulang pada perempuan pascamenopause
Hayati, S., & Herwana, E. (2018) · Jurnal Biomedika dan Kesehatan · doi:10.18051/jbiomedkes.2018.v1.145-151 · Cited by 6
Saul, S. R., & KASE, N. G. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13952 · Cited by 6
Xu, Y., Wang, Q., Hou, G., et al. (2019) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2018.1555857 · Cited by 6
Efficacy and safety of Zuogui Pill in treating osteoporosis
Chen, G., Zhang, Z., Liu, Y., Lu, J., Qi, X., Fang, C., & Zhou, C. (2019) · Medicine · doi:10.1097/md.0000000000013936 · Cited by 6
Beck, D., Winzenborg, I., Gao, W., Mostafa, N. M., Noertersheuser, P. A., Chiuve, S. E., Owens, C. D., & Shebley, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.13006 · Cited by 6
Willems, H. C., Munster, B. C. V., Leeflang, M., et al. (2014) · European Journal of Radiology · doi:10.1016/j.ejrad.2014.09.005 · Cited by 6
Fall prevention in older adults
Saccomano, S. J., & Ferrara, L. R. (2015) · The Nurse Practitioner · doi:10.1097/01.npr.0000465117.19783.ee · Cited by 11
Osteoporosis: A Major Problem - Worldwide
AKARIRMAK, Z. Ü. (2018) · Archives of Sports Medicine · doi:10.36959/987/237 · Cited by 6
Prevalence and Risk Factors of Osteoporosis: a Cross-Sectional Study in a Tertiary CenterPreprint
Özmen, S., Kurt, S., Timur, H. T., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4421108/v1 · Cited by 6
Yoo, Y.-S., Kim, M.-G., Park, H.-J., Chae, M.-Y., Choi, Y., Oh, C., Son, C., & Lee, D. W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1413515 · Cited by 5
Goel, B., Virmani, T., Jain, V., Kumar, G., Sharma, A., & Noman, A. A. (2024) · BioMed Research International · doi:10.1155/2024/5594542 · Cited by 7
“Additional reasons include vitamin D insu ffi ciency and a signi fi cant lifestyle including smoking, drinking excessively, and being inactive, all of which raise the risk of BC-associated osteoporosis [17, 18].”
Bone Health for Gynaecologists
Yordanov, A. D., Vasileva‐Slaveva, M., Tsoneva, E., Kostov, S. G., & Yanachkova, V. E. (2025) · Medicina · doi:10.3390/medicina61030530 · Cited by 13
Lycium barbarum Polysaccharide Ameliorates Hindlimb Unloading‐Induced Bone Loss by Targeting Noggin
Sun, C., He, Y., Chen, X., Ding, K., & Chen, C. (2025) · The FASEB Journal · doi:10.1096/fj.202403082r · Cited by 5
Huininga, K., Koromani, F., Zillikens, M., van Velsen, E. V., & Rivadeneira, F. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf120 · Cited by 6
“6 However, using this osteoporosis threshold captures only about 50% of fragility fractures in women.”
Age trend and risk factors of height loss in Chinese over 40 years old
Li, Y., Xu, L., Wang, Q., Luo, C., Yue, C., Liu, H., & Sheng, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1542962 · Cited by 5
“Height loss is a simple, safe and low-cost measurement method, and clinical guidelines often suggest that a series of measurements of height should be taken as part of routine fracture risk assessment (22, 23).”
The Role of Osteoporosis in Spine Surgery and Current Management Strategies: A Review
Bauer, J., Heard, B. J., Singh, H., Mallozzi, S. S., & Moss, I. L. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00930-5 · Cited by 7
“…including dietary modifications, weight-bearing exercise programs, pharmacological therapies, smoking cessation, decreased alcohol consumption, and lifestyle changes, have demonstrated substantial benefits in reduc - ing the incidence of osteoporotic fractures and improving bone health [ 10 ].”
Zhao, W., Wu, Q., Liu, Q., et al. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06486-4 · Cited by 5
Pintus, G., Akram, M. A., Giordo, R., Caggiari, G., & Majdalawieh, A. F. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.11.048 · Cited by 12
Russo, M., Liu, C., Liu, Y., Mahar, S., Rozental, T. D., & Harper, C. M. (2023) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2023.07.006 · Cited by 7
Sharma, J. K., Khan, S., Wilson, T. E., Pilkey, N. G., Kapuria, S., Roy, A., Adams, M. A., & Holden, R. M. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581231212039 · Cited by 5
Liang, Z., Lan, J., Sun, X., Guo, R., Tian, Y., Wang, Y., Liu, Y., & Liu, S. (2024) · Endocrine · doi:10.1007/s12020-024-03871-8 · Cited by 6
Charoenngam, N., Theerakulpisut, D., Rittiphairoj, T., et al. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01425-z · Cited by 5
Application of MRI imaging parameters in lumbar spine diseases: a review of the literature
Feng, N., Li, W., Yu, X. X., et al. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.09.008 · Cited by 5
Marcu, F. M., Paşcalău, N. A., Ilieș, A. B., Antal, I. A., Ianc, D., CIOBANU, D. I., & Suciu, R. N. (2024) · Balneo and PRM Research Journal · doi:10.12680/balneo.2024.718 · Cited by 5
“The decrease in height with age is a natural phenomenon. but a significant loss in height. is a warning sign for a potential diagnosis of osteoporosis [7, 18].”
Wang, J., Zhen, C., Zhang, G., Yang, Z., & Shang, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313136 · Cited by 5
First‐line treatment of osteoporosis with osteoanabolic therapy: a new opportunity
Aleksova, J., & Ebeling, P. R. (2025) · Internal Medicine Journal · doi:10.1111/imj.70061 · Cited by 7
Treatment of osteoporosis in the solid organ transplant recipient: an organ-based approach
Kurnool, S., Shah, N., & Ekanayake, P. S. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251347351 · Cited by 9
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.